Orexo AB Company Description

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally.

Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori.

The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines.

Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Orexo AB (publ)

Country	Sweden
Founded	1994
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	74
CEO	Nikolaj Sorensen

Contact Details

Address: Virdings allé 22 Uppsala, Uppsala County Uppsala County Sweden
Phone	46 1 87 80 88 00
Website	orexo.com

Stock Details

Ticker Symbol	ORX
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0000736415
SIC Code	2834

Key Executives

Name	Position
Nikolaj Sorensen	President and Chief Executive Officer
Fredrik Jarrsten	Executive Vice President and Chief Financial Officer
Cecilia Coupland	Senior Vice President and Head of Operations
Lena Wange	Investor Relations and Communications Director
Robert Ronn	Senior Vice President and Head of Research & Development
Dr. Edward Kim M.B.A., M.D.	Senior Vice President and Chief Medical Officer
Lisa Moore	Senior Vice President of Products and Portfolio Strategy